Blood-based AT(N) biomarkers for Alzheimer's disease and frontotemporal lobar degeneration in Latin America - PubMed
8 days ago
- #Alzheimer's disease
- #Biomarkers
- #Frontotemporal lobar degeneration
- Blood-based AT(N) biomarkers can distinguish Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) in Latin American populations.
- Plasma Aβ42/Aβ40 ratios were reduced, while phosphorylated tau (p-tau217, p-tau181) and neurofilament light chain (NfL) levels were elevated in both AD and FTLD, with NfL showing greater increases in FTLD.
- Classification models achieved ROC AUCs of 83% for AD and 88% for FTLD, with improved accuracy (89% for AD and 95% for FTLD) when combined with neuroimaging and cognitive measures.
- The study highlights the underrepresentation of Latin America in biomarker research despite its genetic and environmental heterogeneity.
- Meta-analyses confirmed consistency of biomarker performance across different Latin American countries.
- Biomarker alterations correlated with executive, memory, and global cognitive impairment.